| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Date of Report (Date of earliest event reported): November 16, 2026 |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the th... |
| 04 Aug 2026 |
8-K: Unregistered Sales of Equity Securities
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock |
| 23 Jun 2026 |
8-K: Regulation FD Disclosure
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension |
| 15 May 2026 |
8-K: Results of Operations and Financial Condition
NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three... |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition
NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the yea... |
| 17 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. |
| 21 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 19 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”), that certain Supplemental Line of Credit Letter Agreement, dated as of March 29, 2024, (the “Supplementa... |
| 08 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company’s directors that had been nominated to serve until the next annual meeting or until their successors are ele... |
| 03 Dec 2025 |
8-K: Regulation FD Disclosure
Since I became President and CEO of Galectin Therapeutics, I can honestly say that I have never been as excited as I am today, nor have I had the luxury of sharing such an extensive amount of meaningful information. As I am writing this ... |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
NORCROSS, Ga., November 14, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the ... |
| 10 Nov 2025 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events... |
| 08 Sep 2025 |
8-K: Regulation FD Disclosure
2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial perf... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
NORCROSS, Ga., August 14, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the th... |
| 09 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”), that certain Supplemental Line of Credit Letter Agreement, dated as of March 29, 2024, (the “Supplementa... |
| 16 Jun 2025 |
8-K: Regulation FD Disclosure
Belapectin for MASH Cirrhosis and Portal Hypertension June 2025 |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three... |
| 12 May 2025 |
8-K: Regulation FD Disclosure; Other Events
2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial perf... |
Loading...